Startseite A comparison of referral patterns to the pediatric endocrine clinic before and after FDA approval of growth hormonefor idiopathic short stature
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

A comparison of referral patterns to the pediatric endocrine clinic before and after FDA approval of growth hormonefor idiopathic short stature

  • Andrea K. Goldyn EMAIL logo , Zeina M. Nabhan und Erica A. Eugster
Veröffentlicht/Copyright: 16. März 2011
Journal of Pediatric Endocrinology and Metabolism
Aus der Zeitschrift Band 24 Heft 1-2

Abstract

Background: Short stature is a common reason for referral to the pediatric endocrine clinic. In 2003, the US Food and Drug Administration (FDA) approved the use of growth hormone (GH) for the treatment of children with idiopathic short stature (ISS).

Objective: To explore if this indication changed referrals for short stature (SS).

Design/Methods: A retrospective chart review of children seen for SS in the pediatric endocrine clinic between July 1998 and June 1999 (interval one, n=138) and July 2005–June 2006 (interval two, n=268) was performed. Variables collected included age, gender, height (h), and parental heights.

Results: Average height standard deviation score (HT-SDS) was –2.11±0.9 in interval one and –2.14±0.83 in interval two (p=ns). No differences in age, gender distribution, relationship between child and parental heights, the proportion of subjects started on GH for ISS or in the HT-SDS of those treated between the two intervals were identified. Nearly half of all children referred in each interval did not meet the technical criteria for short stature.

Conclusions: No differences in referral patterns for SS in our area following FDA approval of GH for ISS were identified. Although referrals appear unchanged, additional investigation of GH prescribing patterns before and after this new indication is needed. Continued education of primary care physicians and the general public regarding the definition of SS and the eligibility for GH therapy should be pursued.


Corresponding author: Andrea K. Goldyn, Section of Pediatric Endocrinology and Diabetology, Department of Pediatrics, James Whitcomb Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, IN, USA Phone: +317-944-3889, Fax: +317-944-3882

Published Online: 2011-03-16
Published in Print: 2011-03-01

©2011 by Walter de Gruyter Berlin New York

Artikel in diesem Heft

  1. Publisher's Note
  2. Publisher's Note
  3. Editorial
  4. Sex steroid priming for growth hormone (GH) provocative tests: an endless debate with insufficient solution
  5. Not ready for prime time
  6. Commentary
  7. Sex hormone priming
  8. Pros of priming in the diagnosis of growth hormone deficiency
  9. Images in Pediatric Endokrinology
  10. Images in pediatric endocrinology: vitamin D deficiency rickets and other nutritional deficiencies in a 12-month-old infant
  11. Original Contributions
  12. The influence of an educational program on the HbA1c-level of adolescents with type 1 diabetes mellitus: a retrospective study
  13. Contribution of clinical, metabolic, and genetic factors on hypertension in obese children and adolescents
  14. Hyperphosphatemic tumoral calcinosis: a 10-year follow-up
  15. Vitamin D deficiency and insulin resistance in obese African- American adolescents
  16. Evaluation of children with nutritional rickets
  17. The effects of delivery route and anesthesia type on early postnatal weight loss in newborns: the role of vasoactive hormones
  18. Abdominal obesity is associated with cardiovascular risk in Japanese children and adolescents
  19. PPAR-γ2 Pro12Ala polymorphism is associated with post-challenge abnormalities of glucose homeostasis in children and adolescents with obesity
  20. The relationship between pubertal gynecomastia, prostate specific antigen, free androgen index, SHBG and sex steroids
  21. Severe hypercalcemia associated with Williams syndrome successfully treated with pamidronate infusion therapy
  22. The subtle signs of Wolfram (DIDMOAD) syndrome: not all juvenile diabetes is type 1 diabetes
  23. The frequency of Hashimoto thyroiditis in children and the relationship between urinary iodine level and Hashimoto thyroiditis
  24. The relationship between serum phosphate levels with childhood obesity and insulin resistance
  25. The relationship of salivary and cord blood cortisol inpreterm infants
  26. A comparison of referral patterns to the pediatric endocrine clinic before and after FDA approval of growth hormonefor idiopathic short stature
  27. Benign transient hyperphosphatasemia in infants and children: a prospective cohort
  28. Carotid arterial stiffness in overweight and obese Indian children
  29. Association study in Taiwanese girls with precocious puberty
  30. Patient Report Letters
  31. A homozygous recurring mutation in WISP3 causing progressive pseudorheumatoid arthropathy
  32. Two pediatric patients with Von Hippel-Lindau disease type 2b: from patient to screening, from screening to patient
  33. Hot Topic
  34. Growth hormone and mortality: the anatomy of a global scare
  35. Meetings
  36. Meetings Calendar
Heruntergeladen am 18.9.2025 von https://www.degruyterbrill.com/document/doi/10.1515/jpem.2011.120/html
Button zum nach oben scrollen